Skip to main content
. Author manuscript; available in PMC: 2016 Jan 2.
Published in final edited form as: Biochem Biophys Res Commun. 2014 Nov 13;456(1):7–12. doi: 10.1016/j.bbrc.2014.11.010

Figure 1. Mdivi-1 enhances TRAIL sensitivity in human ovarian cancer cells but not in non-transformed normal cells.

Figure 1

(A) Human ovarian cancer cells A2780 and cisplatin-resistant A2780cis were treated with increasing doses of TRAIL alone, mdivi-1 alone, or the combination of TRAIL and mdivi-1 for 16 h. Apoptosis was determined by the activity of caspase-3/7. (B) A2780 and A2780cis cells were treated with TRAIL alone, mdivi-1 alone, or the combination for 16 h. Cell survival was measured by CellTiter-Blue. (C) A2780 cells were treated with TRAIL alone, mdivi-1 alone, or the combination at indicated concentrations for 16 h. Apoptosis was determined by staining cells with Annexin V and PI followed by flow cytometry. (D) Normal human dermal fibroblast (NHDF) cells were treated with TRAIL alone, mdivi-1 alone, or the combination for 16 h. Apoptosis and cell viability were determined by the activity of caspase-3/7 and CellTiter-Blue, respectively. Data represent the mean ± S.D. * P<0.05, ** P<0.01, *** P<0.001.